The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden

Abstract

Tumor burden affects the in vivo mechanism of action of CD20 antibodies. Low tumor load can be eliminated by complement alone, whereas elimination of high tumor load requires multiple effector mechanisms.